ESR introduction and
outline ESR Project 13
Born in Isfahan, Iran, she concluded her bachelor in Molecular Genetics in 2014. During her master she studied clinical biochemistry in the medical faculty of Tehran university of medical sciences (TUMS), Tehran, Iran, from 2015-2018. During this time, she investigated the in vitro effects of drugs combination to reduce lipogenesis. She also served as a research assistant in the following projects entitled: “correlation between epigenetics regulation of Nrf2-Keap1 genes and NAFLD”, “function of miRNAs in NAFLD”, and “macrophage polarization in induced inflammation in in vitro and in vivo”. In 2019, as a faculty member in the medical department of Hormozgan University of medical sciences, Iran, she obtained more experience in teaching and researching in molecular medicine.
Since February 2020, she has begun her PhD studies at the Technical University of Munich, Institute of Pharmacology and Toxicology, Germany. She is carrying out her thesis related to cardiovascular disease and non-coding RNA therapy under the supervision of Prof. Dr. Dr. Stefan Engeldhart and Dr. Petros Avramopoulos, in the context of the H2020 TRAIN-HEART project. In her project she focuses on a specific microRNA, miR-27b, which was found to be upregulated in cardiac macrophages in a pressure overload model in mice. She is phenotyping miR-27b-/- macrophages and identifying the targetome of miR-27b. In collaboration with other ERSs she will test different nanoformulations of synthetic miR-27b inhibitors in small and large animal models.
- Hannover Medical School (group of Prof. Thum, Institute of Molecular and Translational Therapeutic Strategies)
Mirabilis Therapeutics BV (Dr Wit, pharmaceutical development)